Fulvestrant: tested in a combination
66 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerNot yet recruitingNCT07937605Phase 2Report a problem
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingNCT07618390Phase 2Report a problem
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingNCT07604272Phase 1Report a problem
- Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNot yet recruitingNCT07333937Phase 2Report a problem
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1Report a problem
- Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female VolunteersRecruitingNCT06995482Phase 1Report a problem
- Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingNCT06849947Phase 2Report a problem
- Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorRecruitingNCT05536128Phase 2Report a problem
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingNCT05524584Phase 2Report a problem
- Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingNCT05362760Phase 4Report a problem
- Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerRecruitingNCT05305924Phase 2Report a problem
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT05113368Phase 2Report a problem
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingNCT04985266Phase 2Report a problem
- Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerRecruitingNCT04646759Phase 3Report a problem
- Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedNCT05082025Phase 2Results postedReport a problem
- Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast CancerTerminatedNCT04305236Phase 2Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerTerminatedNCT04031885Phase 4Results postedReport a problem
- Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerCompletedNCT03643510Phase 2Results postedReport a problem
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerTerminatedNCT03289039Phase 2Results postedReport a problem
- Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast CancerCompletedNCT02953860Phase 2Results postedReport a problem
- Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus PalbociclibCompletedNCT02913430Early Phase 1Results postedReport a problem
- Neoadjuvant Hormonal Therapy Combined With ChemoimmunotherapyTerminatedNCT02345772Phase 1/2Results postedReport a problem
- Endocrine Response in Women With Invasive Lobular Breast CancerCompletedNCT02206984Phase 2Results postedReport a problem
- Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results postedReport a problem
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.TerminatedNCT02000596Phase 2Results postedReport a problem
- Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung CancerTerminatedNCT00932152Phase 2Results postedReport a problem
- Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.CompletedNCT00921115Phase 2Results postedReport a problem
- Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor TherapyTerminatedNCT00722072Phase 2Results postedReport a problem
- Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung CancerTerminatedNCT00592007Phase 2Results postedReport a problem
- Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast CancerCompletedNCT00534417Phase 2Results postedReport a problem
- Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast CancerCompletedNCT00423917Phase 2Results postedReport a problem
- Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast CancerCompletedNCT00259090Phase 2Results postedReport a problem
- Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase InhibitorsCompletedNCT00253422Phase 3Results postedReport a problem
- Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00201864Phase 2Results postedReport a problem
- A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)TerminatedNCT00183963Phase 2Results postedReport a problem
- Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast CancerTerminatedNCT00138125Phase 2Results postedReport a problem
- Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast CancerCompletedNCT00057941Phase 2Results postedReport a problem
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingNCT06110793Phase 1/2Report a problem
- Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast CancerActive, not recruitingNCT05463601Phase 2Report a problem
- SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)Active, not recruitingNCT05392608Phase 2Report a problem
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2Report a problem
- A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive, not recruitingNCT05154487Phase 2Report a problem
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedNCT05063786Phase 3Report a problem
- Fulvestrant + Neratinib In Breast CancerWithdrawnNCT04901299Phase 2Report a problem
- The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast CancerStatus unknownNCT04753177Phase 2/3Report a problem
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingNCT04567420Phase 2Report a problem
- Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2Report a problem
- A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2Report a problem
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1Report a problem
- Fulvestrant in Metastatic Breast CancerStatus unknownNCT03591549Phase 4Report a problem
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast CancerStatus unknownNCT03560856Phase 2Report a problem
- Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaActive, not recruitingNCT03531645Phase 2Report a problem
- Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsActive, not recruitingNCT03393845Phase 2Report a problem
- HR+/HER2- Advanced Breast Cancer and Endocrine ResistanceTerminatedNCT03322215Phase 2Report a problem
- Metformin and Simvastatin in Addition to FulvestrantStatus unknownNCT03192293Phase 2Report a problem
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2Report a problem
- Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT02760030Phase 2Report a problem
- Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3Report a problem
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryActive, not recruitingNCT01953588Phase 3Report a problem
- Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRCompletedNCT01556191Phase 2Report a problem
- Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenStatus unknownNCT01266213Phase 2Report a problem
- Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)CompletedNCT00944918Phase 3Report a problem
- Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast CancerSuspendedNCT00738777Phase 2Report a problem
- Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast CancerCompletedNCT00629616Phase 2Report a problem
- A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast CancerCompletedNCT00234403Phase 2Report a problem
- Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the BreastStatus unknownNCT00126464Not applicableReport a problem